Actavis has a broad product portfolio and strong pipeline with approximately 185 unique ANDAs pending at the FDA, including 49 first-to-files, of which we believe 33 are potential exclusive opportunities.

Our Actavis Pharma R&D strategy focuses on the following product development areas:

• Off-patent drugs that are difficult to develop or manufacture, or that complement or broaden our existing product lines; and
• The development of sustained-release,semi-solid, liquid, oral transmucosal, transdermal, gel, injectable, and other drug delivery technologies and the application of these technologies to proprietary drug forms.